

Jeffrey H Meyer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9947848/publications.pdf>

Version: 2024-02-01

56
papers

4,805
citations

159585

30
h-index

149698

56
g-index

56
all docs

56
docs citations

56
times ranked

5255
citing authors

#	ARTICLE	IF	CITATIONS
1	Imaging of astrocytes in posttraumatic stress disorder: A PET study with the monoamine oxidase B radioligand [¹¹ C]SL25.1188. <i>European Neuropsychopharmacology</i> , 2022, 54, 54-61.	0.7	16
2	In vivo imaging translocator protein (TSPO) in autism spectrum disorder. <i>Neuropsychopharmacology</i> , 2022, 47, 1421-1427.	5.4	10
3	Microglia imaging in methamphetamine use disorder: a positron emission tomography study with the 18 kDa translocator protein radioligand [¹⁸ F]FEPPA. <i>Addiction Biology</i> , 2021, 26, e12876.	2.6	10
4	Recent developments on PET radiotracers for TSPO and their applications in neuroimaging. <i>Acta Pharmaceutica Sinica B</i> , 2021, 11, 373-393.	12.0	82
5	Promising leads and pitfalls: a review of dietary supplements and hormone treatments to prevent postpartum blues and postpartum depression. <i>Archives of Women's Mental Health</i> , 2021, 24, 381-389.	2.6	7
6	Are There Therapeutic Benefits of Cannabinoid Products in Adult Mental Illness?. <i>Canadian Journal of Psychiatry</i> , 2021, 66, 185-194.	1.9	7
7	Inflammation, Obsessive-Compulsive Disorder, and Related Disorders. <i>Current Topics in Behavioral Neurosciences</i> , 2021, 49, 31-53.	1.7	9
8	A double-blind placebo-controlled trial of minocycline on translocator protein distribution volume in treatment-resistant major depressive disorder. <i>Translational Psychiatry</i> , 2021, 11, 334.	4.8	9
9	Potential therapeutic benefits of cannabinoid products in adult psychiatric disorders: A systematic review and meta-analysis of randomised controlled trials. <i>Journal of Psychiatric Research</i> , 2021, 140, 267-281.	3.1	22
10	Autoimmune psychosis: an international consensus on an approach to the diagnosis and management of psychosis of suspected autoimmune origin. <i>Lancet Psychiatry</i> , 2020, 7, 93-108.	7.4	252
11	Replicating predictive serum correlates of greater translocator protein distribution volume in brain. <i>Neuropsychopharmacology</i> , 2020, 45, 925-931.	5.4	20
12	Neuroinflammation in psychiatric disorders: PET imaging and promising new targets. <i>Lancet Psychiatry</i> , 2020, 7, 1064-1074.	7.4	149
13	Translocator Protein Distribution Volume Predicts Reduction of Symptoms During Open-Label Trial of Celecoxib in Major Depressive Disorder. <i>Biological Psychiatry</i> , 2020, 88, 649-656.	1.3	32
14	In Vivo Imaging of Translocator Protein in Long-term Cannabis Users. <i>JAMA Psychiatry</i> , 2019, 76, 1305.	11.0	34
15	Differential levels of prefrontal cortex glutamate+glutamine in adults with antisocial personality disorder and bipolar disorder: A proton magnetic resonance spectroscopy study. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019, 93, 250-255.	4.8	19
16	Classics in Neuroimaging: Development of PET Tracers for Imaging Monoamine Oxidases. <i>ACS Chemical Neuroscience</i> , 2019, 10, 1867-1871.	3.5	42
17	Association of translocator protein total distribution volume with duration of untreated major depressive disorder: a cross-sectional study. <i>Lancet Psychiatry</i> , 2018, 5, 339-347.	7.4	192
18	Elevated monoamine oxidase A activity and protein levels in rodent brain during acute withdrawal after chronic intermittent ethanol vapor exposure. <i>Drug and Alcohol Dependence</i> , 2018, 185, 398-405.	3.2	7

#	ARTICLE	IF	CITATIONS
19	Corticostratial Connectivity in Antisocial Personality Disorder by MAO-A Genotype and Its Relationship to Aggressive Behavior. <i>International Journal of Neuropsychopharmacology</i> , 2018, 21, 725-733.	2.1	17
20	Subchronic glucocorticoids, glutathione depletion and a postpartum model elevate monoamine oxidase a activity in the prefrontal cortex of rats. <i>Brain Research</i> , 2017, 1666, 1-10.	2.2	7
21	Inflammation in the Neurocircuitry of Obsessive-Compulsive Disorder. <i>JAMA Psychiatry</i> , 2017, 74, 833.	11.0	132
22	Novel Phenotypes Detectable with PET in Mood Disorders. <i>PET Clinics</i> , 2017, 12, 361-371.	3.0	2
23	Selective dietary supplementation in early postpartum is associated with high resilience against depressed mood. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 3509-3514.	7.1	25
24	Neuroprogression and Immune Activation in Major Depressive Disorder. <i>Modern Problems of Pharmacopsychiatry</i> , 2017, 31, 27-36.	2.5	25
25	Imaging Microglial Activation in Untreated First-Episode Psychosis: A PET Study With [¹⁸ F]FEPPA. <i>American Journal of Psychiatry</i> , 2017, 174, 118-124.	7.2	103
26	Occupancy of Norepinephrine Transporter by Duloxetine in Human Brains Measured by Positron Emission Tomography with (S,S)-[¹⁸ F]FMeNER-D2. <i>International Journal of Neuropsychopharmacology</i> , 2017, 20, 957-962.	2.1	35
27	Increased Seasonal Variation in Serotonin Transporter Binding in Seasonal Affective Disorder. <i>Neuropsychopharmacology</i> , 2016, 41, 2447-2454.	5.4	40
28	Association of ventral striatum monoamine oxidase-A binding and functional connectivity in antisocial personality disorder with high impulsivity: A positron emission tomography and functional magnetic resonance imaging study. <i>European Neuropsychopharmacology</i> , 2016, 26, 777-786.	0.7	26
29	Elevated Monoamine Oxidase-A Distribution Volume in Borderline Personality Disorder Is Associated With Severity Across Mood Symptoms, Suicidality, and Cognition. <i>Biological Psychiatry</i> , 2016, 79, 117-126.	1.3	35
30	Monoamine Oxidase-A Occupancy by Moclobemide and Phenzelzine: Implications for the Development of Monoamine Oxidase Inhibitors. <i>International Journal of Neuropsychopharmacology</i> , 2016, 19, pyv078.	2.1	27
31	Imaging Neuroinflammation in Gray and White Matter in Schizophrenia: An In-Vivo PET Study With [¹⁸ F]-FEPPA. <i>Schizophrenia Bulletin</i> , 2015, 41, 85-93.	4.3	158
32	Evidence Revealing Deregulation of The KLF11-Mao A Pathway in Association with Chronic Stress and Depressive Disorders. <i>Neuropsychopharmacology</i> , 2015, 40, 1373-1382.	5.4	35
33	Relationship of Monoamine Oxidase-A Distribution Volume to Postpartum Depression and Postpartum Crying. <i>Neuropsychopharmacology</i> , 2015, 40, 429-435.	5.4	67
34	Role of Translocator Protein Density, a Marker of Neuroinflammation, in the Brain During Major Depressive Episodes. <i>JAMA Psychiatry</i> , 2015, 72, 268.	11.0	700
35	No effect of oral l-tryptophan or alpha-lactalbumin on total tryptophan levels in breast milk. <i>European Neuropsychopharmacology</i> , 2015, 25, 779-787.	0.7	14
36	Elevated Monoamine Oxidase A Binding During Major Depressive Episodes Is Associated with Greater Severity and Reversed Neurovegetative Symptoms. <i>Neuropsychopharmacology</i> , 2014, 39, 973-980.	5.4	53

#	ARTICLE	IF	CITATIONS
37	Kinetic Modeling of the Monoamine Oxidase B Radioligand [¹¹ C]SL25.1188 in Human Brain with High-Resolution Positron Emission Tomography. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2014, 34, 883-889.	4.3	83
38	Greater Monoamine Oxidase A Binding in Perimenopausal Age as Measured With Carbon 11-Labelled Harmine Positron Emission Tomography. <i>JAMA Psychiatry</i> , 2014, 71, 873.	11.0	58
39	Greater Monoamine Oxidase A Binding in Alcohol Dependence. <i>Biological Psychiatry</i> , 2014, 75, 756-764.	1.3	21
40	No effect of oral tyrosine on total tyrosine levels in breast milk: implications for dietary supplementation in early postpartum. <i>Archives of Women's Mental Health</i> , 2014, 17, 541-548.	2.6	8
41	Effect of dysfunctional attitudes and postpartum state on vulnerability to depressed mood. <i>Journal of Affective Disorders</i> , 2014, 161, 16-20.	4.1	8
42	Serotonin transporter occupancy of SKL10406 in humans: comparison of pharmacokinetic-pharmacodynamic modeling methods for estimation of occupancy parameters. <i>Translational and Clinical Pharmacology</i> , 2014, 22, 83.	0.9	1
43	Neurochemical Imaging and Depressive Behaviours. <i>Current Topics in Behavioral Neurosciences</i> , 2012, 14, 101-134.	1.7	10
44	Quantitation of Translocator Protein Binding in Human Brain with the Novel Radioligand [¹⁸ F]-FEPPA and Positron Emission Tomography. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2011, 31, 1807-1816.	4.3	98
45	Radiosynthesis of [¹¹ C]SL25.1188 via [¹¹ C]CO ₂ fixation for imaging monoamine oxidase B. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2011, 54, 678-680.	1.0	67
46	Elevated Brain Monoamine Oxidase A Binding in the Early Postpartum Period. <i>Archives of General Psychiatry</i> , 2010, 67, 468.	12.3	177
47	Brain Monoamine Oxidase A Binding in Major Depressive Disorder. <i>Archives of General Psychiatry</i> , 2009, 66, 1304.	12.3	166
48	Applying Neuroimaging Ligands to Study Major Depressive Disorder. <i>Seminars in Nuclear Medicine</i> , 2008, 38, 287-304.	4.6	52
49	Serotonin _{2A} receptor binding potential in people with aggressive and violent behaviour. <i>Journal of Psychiatry and Neuroscience</i> , 2008, 33, 499-508.	2.4	39
50	Elevated Monoamine Oxidase A Levels in the Brain. <i>Archives of General Psychiatry</i> , 2006, 63, 1209.	12.3	507
51	Elevated Putamen D ₂ Receptor Binding Potential in Major Depression With Motor Retardation: An [¹¹ C]Raclopride Positron Emission Tomography Study. <i>American Journal of Psychiatry</i> , 2006, 163, 1594-1602.	7.2	139
52	Serotonin Transporter Occupancy of Five Selective Serotonin Reuptake Inhibitors at Different Doses: An [¹¹ C]DASB Positron Emission Tomography Study. <i>American Journal of Psychiatry</i> , 2004, 161, 826-835.	7.2	464
53	Dysfunctional Attitudes and 5-HT ₂ Receptors During Depression and Self-Harm. <i>American Journal of Psychiatry</i> , 2003, 160, 90-99.	7.2	254
54	Bupropion occupancy of the dopamine transporter is low during clinical treatment. <i>Psychopharmacology</i> , 2002, 163, 102-105.	3.1	134

#	ARTICLE	IF	CITATIONS
55	Modeling of Receptor Ligand Data in PET and SPECT Imaging: A Review of Major Approaches. Journal of Neuroimaging, 2001, 11, 30-39.	2.0	29
56	β -blocker Binding to Human 5-HT _{1A} Receptors in vivo and in vitro Implications for Antidepressant Therapy. Neuropsychopharmacology, 2000, 23, 285-293.	5.4	70